Patents by Inventor Gerard Raphael Dawson

Gerard Raphael Dawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of a GABAA &agr;5 inverse agonist and a muscarinic agonist
    Patent number: 6455552
    Abstract: A combination of a muscarinic agonist and an inverse agonist of the GABAA &agr;5 receptor subtype useful in treating neurodegenerative conditions such as Alzheimer's Disease is disclosed.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: September 24, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Gerard Raphael Dawson
  • Preparation and use of a specific GABA-A&agr;5 receptor ligand for treatment of Alzheimer's disease
    Patent number: 6426343
    Abstract: The present invention relates to a method of enhancing cognition without producing convulsions which method comprises administering to a subject in need thereof a cognition enhancing amount of a compound which is a GABAa selective alpha5 receptor inverse agonist.
    Type: Grant
    Filed: July 24, 1997
    Date of Patent: July 30, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Gerard Raphael Dawson
  • Combination of a GABA-A &agr; 2/3 agonist and a selective serotonin reuptake inhibitor
    Patent number: 6399608
    Abstract: A pharmaceutical product comprising an SSRI and a non-sedating anxiolytic compound, which is a modulator of the benzodiazepine binding site of the human GABAA receptor, having a binding affinity for the &agr;3 subunit of the human GABAA receptor of 10 nM or less, which elicits at least a 40% potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the &agr;3 subunit of &agr;3 and which elicits at most a 30% potentiation of the GABA EC20 response in stably transfected cell lines expressing the &agr;1 subunit of the human GABAA receptor is disclosed for simultaneous, separate or sequential administration.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Gerard Raphael Dawson
  • Preparation and use of a specific GABA-A&agr;5 receptor ligand for treatment of alzheimer's disease
    Patent number: 6323198
    Abstract: A method of treatment for enhancing cognition in the treatment of Alzheimer's disease, for example, employs a specific GABAA Alpha5 receptor ligand.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: November 27, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventor: Gerard Raphael Dawson
  • Method of enhancing cognition with 2-(4-methoxyphenyl)-pyrazolo[4,3-c]quinolin-3-one
    Patent number: 6087372
    Abstract: The present invention provides the use of 2-(4-methoxyphenyl)-pyrazolo[4,3-c]quiniolin-3-one or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for enhancing cognition, particularly in Alzheimer's Disease, a method of enhancing cognition and pharmaceutically acceptable salts such as the hemi camphor sulfonate.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: July 11, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Gerard Raphael Dawson, Angus Murray MacLeod, Guy Ralph Seabrook